Pharmaceutical industry in China

Checkmate Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference

Retrieved on: 
Monday, August 2, 2021

Checkmate Pharmaceuticals Inc. (NASDAQ: CMPI) (Checkmate), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that Barry Labinger, CEO, will present at the BTIG Virtual Biotechnology Conference from 3:30-3:55pm ET on Monday, August 9, 2021.

Key Points: 
  • Checkmate Pharmaceuticals Inc. (NASDAQ: CMPI) (Checkmate), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that Barry Labinger, CEO, will present at the BTIG Virtual Biotechnology Conference from 3:30-3:55pm ET on Monday, August 9, 2021.
  • Checkmate will also host 1x1 investor meetings during the conference.
  • Checkmate Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer.
  • The information that Checkmate Pharmaceuticals posts on these channels and websites could be deemed to be material information.

Currax Pharmaceuticals Moves Global Headquarters to Brentwood, Tennessee

Retrieved on: 
Monday, August 2, 2021

BRENTWOOD, Tenn., Aug. 2, 2021 /PRNewswire/ --Currax Pharmaceuticals, LLC ("Currax"), a specialty biopharmaceutical company dedicated to expanding access to clinically differentiated, underappreciated medicines both branded and generic announces today the relocation of its corporate headquarters from Morristown, New Jersey, to Brentwood, Tennessee.

Key Points: 
  • BRENTWOOD, Tenn., Aug. 2, 2021 /PRNewswire/ --Currax Pharmaceuticals, LLC ("Currax"), a specialty biopharmaceutical company dedicated to expanding access to clinically differentiated, underappreciated medicines both branded and generic announces today the relocation of its corporate headquarters from Morristown, New Jersey, to Brentwood, Tennessee.
  • "Currax is excited to join the growing healthcare and pharmaceutical community in Tennessee and looks forward to taking a leading role in the continued development of the sector within the region.
  • Currax's new headquarters will have approximately 35 employees and will serve as the central office for leadership and home office teams.
  • Currax Pharmaceuticals LLC is a specialty pharmaceutical business focused on acquiring and commercializing prescription Medicines worldwide.

Rafarma Signs Trilateral Investment Agreement Officially Launching Tashkent Pharmaceutical Plant Build

Retrieved on: 
Friday, July 30, 2021

Rafarma Pharmaceuticals previously announced its plans to build a scientific and pharmaceutical complex on the territory of Tashkent Pharma Park by the end of 2026.

Key Points: 
  • Rafarma Pharmaceuticals previously announced its plans to build a scientific and pharmaceutical complex on the territory of Tashkent Pharma Park by the end of 2026.
  • The trilateral agreement was signed July 24, 2020 by representatives of Rafarma Pharmaceuticals, the Agency for the Development of the Pharmaceutical Industry of Uzbekistan and the Directorate for the Development of the Innovative Scientific and Production Pharmaceutical Cluster Tashkent Pharma Park.
  • The total investment will amount to $85 million (US), work on the project commences this year.
  • Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934.

Universe Pharmaceuticals INC to Announce Unaudited Financial Results for The First Six Months of Fiscal Year 2021 on August 2, 2021

Retrieved on: 
Friday, July 30, 2021

Jian, Jiangxi, China, July 30, 2021 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the Company) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that it will release its unaudited financial results for the first six months of fiscal year 2021 ended March 31, 2021 on Monday, August 2, 2021 before the market opens.

Key Points: 
  • Jian, Jiangxi, China, July 30, 2021 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the Company) (Nasdaq: UPC), a pharmaceutical producer and distributor in China, today announced that it will release its unaudited financial results for the first six months of fiscal year 2021 ended March 31, 2021 on Monday, August 2, 2021 before the market opens.
  • The Company intends to file its financial results on Form 6-K with the Securities and Exchange Commission and release its earnings press release accordingly.
  • Universe Pharmaceuticals INC, headquartered in Jian, Jiangxi, China, is a pharmaceutical producer and distributor in China.
  • The Company also distributes and sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies.

Adhera Signs Definitive License Agreement with Melior Pharmaceuticals II for New Parkinson’s Disease Drug Candidate

Retrieved on: 
Thursday, July 29, 2021

To the best of either companies knowledge, MLR-1019 will be the only drug candidate in development that addresses both movement (e.g., facial masking, dyskinesia, etc.)

Key Points: 
  • To the best of either companies knowledge, MLR-1019 will be the only drug candidate in development that addresses both movement (e.g., facial masking, dyskinesia, etc.)
  • Melior Discovery and its companies, Melior Pharmaceuticals I, Inc. and Melior Pharmaceuticals II, LLC, are leaders in pharmaceutical drug repositioning using the unique theraTRACE platform comprised of multiplexed in vivo disease models.
  • Melior Discovery and Melior Pharmaceuticals are privately held and located in Exton, PA. For more information, visit www.meliordiscovery.com and www.meliorpharma.com .
  • A more complete description of these risk factors is included in Adhera Therapeutics filings with the Securities and Exchange Commission.

Concert Pharmaceuticals to Report Second Quarter 2021 Results on August 5, 2021

Retrieved on: 
Thursday, July 29, 2021

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the second quarter of 2021, on Thursday, August 5, 2021, before the U.S. financial markets open.

Key Points: 
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the second quarter of 2021, on Thursday, August 5, 2021, before the U.S. financial markets open.
  • ET to discuss its second quarter 2021 financial results and provide a business update.
  • Individuals interested in participating in the call should dial (855) 354-1855 (U.S. and Canada) or (484) 365-2865 (International).
  • Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform (deuterated chemical entity platform).

TFF Pharmaceuticals to Participate in the BTIG Virtual Biotechnology Conference

Retrieved on: 
Wednesday, July 28, 2021

BTIG Virtual Biotechnology Conference August 9-10, 2021

Key Points: 
  • BTIG Virtual Biotechnology Conference August 9-10, 2021
    If you are interested in arranging a one-on-one meeting, please contact your BTIG conference representative.
  • TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform.
  • TFF Pharmaceuticals has two lead drug candidates: Voriconazole Inhalation Powder and Tac-Lac Inhalation Powder.
  • To learn more about TFF Pharmaceuticals and its product candidates, visit the Companys website at https://tffpharma.com .

Novita Pharmaceuticals and China Resources Double Crane Pharmaceutical Enter into an Exclusive License Agreement to Develop and Commercialize Fascin Inhibitor in China

Retrieved on: 
Wednesday, July 28, 2021

CRDC will receive the rights to research, develop, manufacture, and exclusively commercialize Novita's fascin inhibitor in oncology applications in the Greater China region.

Key Points: 
  • CRDC will receive the rights to research, develop, manufacture, and exclusively commercialize Novita's fascin inhibitor in oncology applications in the Greater China region.
  • In addition to excellent safety and pharmacokinetic profiles, NP-G2-044 has shown preliminary and exciting signals of efficacy in late-stage cancer patients.
  • "Novita is delighted to license our first-in-class fascin inhibitor to one of the largest pharmaceutical companies in China," said Jillian Zhang, Ph.D., President and Chief Scientific Officer of Novita.
  • About China Resources Double Crane Pharmaceutical Co., Ltd.
    China Resources Double Crane Pharmaceutical Co., Ltd. ("CRDC"), established in 1939 and headquartered in Beijing, China, has 21 subsidiaries and more than 11,000 employees throughout the country.

Vivera Pharmaceuticals Responds to New Safety Protocols with Expanded Access to COVID-19 Testing, Vaccines, and Personal Protective Equipment

Retrieved on: 
Wednesday, July 28, 2021

NEWPORT BEACH, Calif., July 28, 2021 /PRNewswire/ --In response to new nationwide mask and testing mandates, Vivera Pharmaceuticals has expanded access to testing resources, vaccine clinics, and personal protective equipment (PPE).

Key Points: 
  • NEWPORT BEACH, Calif., July 28, 2021 /PRNewswire/ --In response to new nationwide mask and testing mandates, Vivera Pharmaceuticals has expanded access to testing resources, vaccine clinics, and personal protective equipment (PPE).
  • Vivera is proud to have established a winning portfolio of USA-made testing products.
  • Vivera understands that regular testing is one of the best ways to control the spread of the virus.
  • Vivera Pharmaceuticals is vertically integrated with patented technology, manufacturing capabilities, and distribution for its products.

Worldwide Pharmaceutical Logistics Industry to 2026 - Strong Cooperation Among the Cold Chain Partners Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 28, 2021

What are the inhibiting factors and impact of COVID-19 shaping the Global Pharmaceutical Logistics Market during the forecast period?

Key Points: 
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Pharmaceutical Logistics Market during the forecast period?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Pharmaceutical Logistics Market?
  • What is the competitive strategic window for opportunities in the Global Pharmaceutical Logistics Market?
  • What modes and strategic moves are considered suitable for entering the Global Pharmaceutical Logistics Market?